Universität zu Köln

Reher, Dominik, Fehrenbach, Uli, Kayser, Antonin, Pape, Ulrich-Frank, Henes, Frank Oliver, Cremer, Birgit, Hoersch, Dieter, Izbicki, Jakob, Lohse, Ansgar Wilhelm, Rinke, Anja and Schrader, Joerg . Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours. Neuroendocrinology. BASEL: KARGER. ISSN 1423-0194

Full text not available from this repository.

Abstract

Introduction: Incidence of pancreatic neuroendocrine tumours (pNETs) is on the rise. The only curative treatment is surgical resection in localized or oligo-metastatic disease. However, patients may present with locally advanced or unresectable primary tumours. So far, no conversion therapy to achieve resectability has been established, which is partly due to lack of data on primary tumour response to therapies. Here, we specifically evaluate the primary tumour response to streptozocin/5-FU in a large cohort of metastatic pNET patients. Methods: Five ENETS centres in Germany contributed 84 patients to the study cohort for retrospective analysis. Results: Overall response rate (ORR) in primary tumours was 34% and disease control rate (DCR) 88%. ORR was different in metastases at 44% and DCR at 70%. Partial remission in primary tumours was more frequent among those located in pancreatic tail than that in pancreatic head (49% vs. 14%, p = 0.03). Correspondingly, metastases from tumours originating from pancreatic tail responded more frequently than metastases originating from pancreatic head (88.5% vs. 41.7%, p = 0.005). The median PFS of the primary tumours was longer than that in metastases (31 months vs. 16 months; p = 0.04). Considerable downsizing of the primary tumour was rare and occurred primarily in tumours located in the pancreatic tail. Conclusion: STZ/5-FU can achieve disease stabilization in a high proportion of metastatic pNET patients. In the majority of cases however it does not induce substantial downsizing of the primary tumour, thus possibly limiting its potential as conversion chemotherapy. Furthermore, the difference in response rate observed between different primary tumour locations warrants further exploration.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Reher, Dominik UNSPECIFIED UNSPECIFIED UNSPECIFIED Fehrenbach, Uli UNSPECIFIED UNSPECIFIED UNSPECIFIED Kayser, Antonin UNSPECIFIED UNSPECIFIED UNSPECIFIED Pape, Ulrich-Frank UNSPECIFIED UNSPECIFIED UNSPECIFIED Henes, Frank Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Cremer, Birgit UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoersch, Dieter UNSPECIFIED UNSPECIFIED UNSPECIFIED Izbicki, Jakob UNSPECIFIED UNSPECIFIED UNSPECIFIED Lohse, Ansgar Wilhelm UNSPECIFIED UNSPECIFIED UNSPECIFIED Rinke, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Schrader, Joerg UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-594793
DOI:	10.1159/000518895
Journal or Publication Title:	Neuroendocrinology
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	1423-0194
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CONSENSUS GUIDELINES UPDATE; PROGNOSTIC-FACTORS; LIVER METASTASES; GASTROENTEROPANCREATIC TUMORS; INTERFERON-ALPHA; STREPTOZOCIN; MANAGEMENT; FLUOROURACIL; CHEMOTHERAPY; DOXORUBICIN Multiple languages Endocrinology & Metabolism; Neurosciences Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59479